Insulin therapy improves cardiac autonomic function in type 2 diabetic patients;Neu initiierte insulintherapie und kardiale autonome funktion bei typ-2-diabetes

Herz

Volumn 29, Issue 5, 2004, Pages 519-523

  Schnell, Oliver ^a   Kilinc, Sonja ^b   Rambeck, Aurel ^b   Standl, Eberhard ^a  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^b Institut für Diabetesforschung ^*

Author keywords

Diabetes; Heart; Insulin; Neuropathy

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART AUTOMATICITY; HEART INNERVATION; HEART RATE VARIABILITY; HUMAN; HYPERPNEA; INSULIN TREATMENT; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK ASSESSMENT; SCINTIGRAPHY; SYMPATHETIC REFLEX; SYSTOLIC BLOOD PRESSURE;

ADULT; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 4444236193     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2612-2     Document Type: Article

References (23)

1. Standl E, Schnell O. A new look upon the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000;43:1455-69.
2. Schnell O, Schäfer O, Kleybrink S, et al. Intensification of therapeutic approaches reduce mortality in diabetic patients with acute myocardial infarction: the Munich Registry. Diabetes Care 2004;27:455-60.
3. Van den Berghe BC, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
4. Van den Berghe BC, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003;31:359-66.
5. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DICAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 1996;17:1337-44.
6. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999;99:2626-32.
7. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation J Am Coll Cardiol 2003;41:1404-7.
8. Sundell J, Laine H, Nuutila P, et al. The effects of insulin and short-term hyperglycaemia on myocardial blood flow in young men with uncomplicated type I diabetes. Diabetologia 2002;45:775-82.
9. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.
10. Scherbaum W, Landgraf W. Praxisleitlinien der Deutschen Diabetes Gesellschaft. Diabetes Stoffw 2002;11:Suppl 2:1-39.
11. Schnell O, Kirsch C-M, Stemplinger J, et al. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term type 1 diabetic patients with and without ECC-based autonomic neuropathy. Diabetologia 1995;38:1345-52.
12. 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 1996;45:801-5.
13. Ziegler D, Laux C, Dannehl K, et al. Assessment of cardiovascular function. Age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992;9:166-75.
14. Schnell O, Muhr D, Dresel S, et al. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin dependent (type 1) diabetes mellitus at one-year follow-up. Diabet Med 1997;14:57-62.
15. Muhr-Becker D, Weiss M, Tatsch K, et al. Scintigraphically assessed cardiac sympathetic dysinnervation in poorly controlled type 1 diabetes mellitus: one-year follow-up with improved metabolic control. Exp Clin Endocrinol Diabetes 1999;107:306-12.
16. The St Thomas's Diabetic Study Group. Failure of improved glycaemic control to reverse diabetic autonomic neuropathy. Diabet Med 1986;3:330-4.
17. Nusser J, Scheuer R, Abendroth D, et al. Effect of pancreatic and/or renal transplantation on diabetic autonomic neuropathy. Diabetologia 1991;34: Suppl 1:S118-20.
18. Hattori N, Schnell O, Bengel FM, et al. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur J Nucl Med Mol Imaging 2002;29:891-8.
19. Momose M, Abletshauser C, Neverve J, et al. Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med 2002;29:1675-9.
20. Meier M, Linke R, Tatsch K, et al. An advanced approach for the assessment of gastric motor function in long-term type 1 diabetes mellitus with and without autonomic neuropathy. Clin Auton Res 2002;12:197-202.
21. Thilo C, Standl E, Knez E, et al. Coronary calcification in long-term type 1 diabetic patients - a study with multi slice spiral computed tomography. Exp Clin Endocrinol Diabetes 2004:in press.
22. Caede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
23. Otter W, Kleybrink S, Doering W, et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med 2004;21:183-7.